Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Vaccinations01:51

Vaccinations

53.0K
Overview
53.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Controversial Link Between Human Papillomavirus Infection and Esophageal Health: An Exploratory Translational Study.

Pathogens (Basel, Switzerland)·2026
Same author

Filamentous virions act as non-infectious interfering particles to modulate papillomavirus infection.

Journal of virology·2026
Same author

Nano-Luciferase complementation assay of human herpesvirus 8 chemo/cytokine-receptor interactions.

Scientific reports·2025
Same author

Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.

JCO global oncology·2025
Same author

A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer.

Gynecologic oncology·2025
Same author

German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2025

Related Experiment Video

Updated: Mar 11, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K

Developments in L2-based human papillomavirus (HPV) vaccines.

Christina Schellenbacher1, Richard B S Roden2, Reinhard Kirnbauer1

  • 1Laboratory of Viral Oncology (LVO), Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Austria.

Virus Research
|November 28, 2016
PubMed
Summary

Current Human Papillomavirus (HPV) vaccines target specific types, leaving many cancers and warts unprotected. Research focuses on the minor capsid protein L2 to develop broader-spectrum HPV vaccines with improved cross-protection.

Keywords:
Cervical cancer (CxCa)Cutaneous and anogenital warts (condylomata)HPV infection and diseaseHuman papillomavirus (HPV) vaccineMinor capsid protein (L2)Squamous cell cancer (SCC)

More Related Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.1K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K

Related Experiment Videos

Last Updated: Mar 11, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.9K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.1K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K

Area of Science:

  • Virology
  • Immunology
  • Oncology

Background:

  • High-risk Human Papillomavirus (hrHPV) infections cause significant cancer burdens globally, including cervical, ano-genital, and oro-pharyngeal carcinomas.
  • Licensed HPV vaccines, based on L1 virus-like particles (VLPs), offer protection against specific HPV types but have limitations in spectrum and cross-protection.

Purpose of the Study:

  • To review efforts aimed at developing broader-spectrum HPV vaccines.
  • To explore the potential of the minor capsid protein L2 for inducing cross-neutralizing antibodies against diverse HPV types.

Main Methods:

  • Review of existing literature on HPV vaccines, L1-VLP technology, and L2 protein immunogenicity.
  • Analysis of studies investigating L2-based vaccine candidates and their cross-protective capabilities in animal models.

Main Results:

  • Current L1-VLP vaccines are limited by manufacturing complexity and do not cover all oncogenic or cutaneous HPV types, nor beta-papillomaviruses (betaPVs).
  • The L2 protein contains type-common epitopes that elicit broadly cross-neutralizing antibodies, offering potential for wider protection.
  • Challenges remain in enhancing the low immunogenicity of L2 peptides for effective vaccine development.

Conclusions:

  • Developing broader-spectrum HPV vaccines targeting L2 is crucial to address currently unprotected HPV types and betaPVs.
  • Further research into L2 immunogenicity and formulation is needed to create more comprehensive HPV vaccines for cancer prevention.